Novo Nordisk Q1 Sales Beat Estimates on Weight Loss Pill Demand
Novo Nordisk reported first-quarter sales of its oral Wegovy pill at $353 million, more than double analyst expectations. The strong performance led the Danish pharmaceutical company to raise its full-year outlook, causing shares to surge. The results underscore growing demand for weight loss treatments.
Key facts
- First-quarter sales of oral Wegovy pill: $353 million
- Sales more than doubled analyst expectations
- Novo Nordisk lifted its full-year outlook
- Shares surged following the earnings report
- Company is based in Denmark
- Wegovy is a weight loss drug
- Oral formulation of Wegovy was a key driver
- Results reflect strong demand for weight loss medications
Entities
Institutions
- Novo Nordisk
Locations
- Denmark
Sources
- Quartz —